Silo Pharma is embarking on a preclinical toxicity study of its novel time-released, dosage-controlled formulation of ketamine – SP-26 – for the treatment of fibromyalgia.
MindMed has initiated a Phase 1 investigator-initiated trial led by collaborator Professor Dr Matthias Liechti at University Hospital Basel (UHB).
Silo Pharma is preparing a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA) for a novel topical...
Chief clinical development officer of HMNC Brain Health, Hans Eriksson, speaks to Psychedelic Health about how the company’s formula, ‘Ketabon’, will provide the therapeutic benefits of ketamine without...
A team of scientists has developed LSD-like compounds that fit into the 5HT2a receptor – the main target of substances such as LSD and psilocybin.
atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial...
Optimi Health Corp.
Results from a new study suggest that the antidepressant effects of ketamine can be prolonged in people with treatment-resistant depression through computer-based neurocognitive training.
Small Pharma has completed enrollment in its Phase 2a clinical trial of its intravenous formulation of DMT – candidate SPL026 – with psychotherapy for the treatment...
The ‘Microdosing and Meditation Study’ is aiming to observe how meditation skills evolve over three months of regular meditation practice and whether, how, and for whom...